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A multi-analyte LC-MS/MS method for screening and
quantiﬁcation of nitrosamines in sartans
Shu-Han Chang, Ching-Chia Chang, Li-Jing Wang, Wei-Ching Chen, Shu-Yu Fan,
Chi-Zong Zang*, Ya-Hui Hsu, Mei-Chih Lin, Su-Hsiang Tseng, Der-Yuan Wang
Food and Drug Administration, Ministry of Health and Welfare, Executive Yuan, 161-2 Kunyang St., Nangang Dist., Taipei 11561,
Taiwan

Abstract
An incident of sartan medicine contamination was notiﬁed by Europe in June 2018. The contaminant was identiﬁed
as a probable carcinogenic nitrosamine and the recalls of sartan medicines were soon made. Since then, more nitrosamine contaminants in sartan medicines were reported. To broaden the applicability and variety in nitrosamine
determination, a multi-analyte method is required. In this study, a feasible and sensitive multi-analyte LC-MS/MS
method for determination of 12 nitrosamines in sartans was established, where the active pharmaceutical ingredients
and ﬁnal products merchandised in Taiwan were also examined. Chromatographic separation was achieved on an
Xselect® HSS T3 column (15 cm £ 3 mm i.d., 3.5 mm) with gradient elution using mobile phase A consisting of 0.1%
formic acid in water and mobile phase B consisting of 0.1% formic acid in acetonitrile/methanol (2:8). Validation of the
proposed method was also carried out. The limit of detection and limit of quantiﬁcation for 12 nitrosamines were
20 ng/g and 50 ng/g, respectively. The intra-day and inter-day recoveries of nitrosamines were among 80e120% with
precision of 20% for most nitrosamines within sartans matrices. The method was successfully established and applied
to authentic samples which a total of 98 positive samples containing 5 distinct nitrosamines, including N-nitrosodiethylamine, N-nitrosodimethylamine, N-nitroso-N-methyl-4-aminobutyric acid, N-nitrosomorpholine and Nnitrosopiperidine, were detected from 557 authentic samples.
Keywords: Carcinogens, Liquid chromatography, Mass spectrometry, Nitrosamines, Sartans

1. Introduction

A

ngiotensin II is a biologically active
component that plays an important role in
the regulation of blood pressure, secretion of
aldosterone, and homeostasis of ﬂuid in human
body. Besides, it is an etiological factor for cardiovascular diseases [1]. Angiotensin II receptor
blockers (ARBs), also known as angiotensin II receptor type 1 antagonists or “sartans”, have been
widely applied for treating cardiovascular diseases
such as hypertension, heart failure, myocardial
infarction, and diabetic nephropathy [1e3]. To
date, several sartans, such as losartan and valsartan, have been launched by many countries [4].

These agents have been manufactured for years
where impurities and related substances are found
as analogs or degraded fragments of sartans [5e8].
Recently, unexpected carcinogenic impurities were
detected in sartan medicines. Those compounds
were further identiﬁed as nitrosamine analogs Nnitrosodiethylamine
(NDEA)
and
N-nitrosodimethylamine (NDMA). Those nitrosamine
impurities are produced as by-products resulted
from the alteration of the manufacturing processes
[9,10]. Generally, nitrosamines are found in natural
environment and industrial manufacturing, such
as pesticides, rubbers, dyes, and pharmaceuticals
[11,12]. In industry, nitrosamines are inferred to
forming in manufacturing processes that employ
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amines, nitrates, and nitrites under a wide range of
pH levels, via different mechanisms such as
nitrosation by nitrite [13,14]. Oxidation of unsymmetrical dimethylhydrazine (UDMH) also affords
nitrosamines [15]. For sartans, the application of
alternative solvents in sartan production led to the
production of nitrosamines, for example, NDMA
was generated from dimethylformamide (DMF)
and NDEA was generated from triethylamine
(TEA) [16]. Nitrosamines are considered as potential human carcinogens and the cancer risk has
been estimated which the excess lifetime is 105 to
106 in the concentration range 0.7e100 ng/L
(drinking water) [17e19]. The risk of nitrosamines
for human health has been highly dressed that
many governments impose strict regulations on
nitrosamines. For example, NDEA and NDMA are
categorized as Group 2A substances (probably
carcinogenic to humans) by International Agency
for Research on Cancer (IARC) of WHO, category
1B by the European Union (Presumed to have
carcinogenic potential for humans), and category
B2 (probable human carcinogen) by U.S.; besides,
N-nitrosodipropylamine
(NDPA),
N-nitrosomethylethylamine (NMEA), N-nitrosomorpholine (NMOR), N-nitrosopiperidine (NPIP) and Nnitrosopyrrolidine (NPYR) are categorized as B2
level by IARC [19]. As a consequence, U.S. EPA
(Environmental Protection Agency) incorporates 6
nitrosamines in the regulation, including N-nitrosodibutylamine (NDBA), NDEA, NDMA, NDPA,
NMEA and NPYR [20]. Due to the probable hazard
to human body, limits of nitrosamines in sartans
were regulated that U.S. FDA drew up an interim
limit which the acceptable intakes for NDEA,
NDMA and NMBA in 8 sartans are 26.5, 96 and
96 ng/day, respectively [21].
The recent incident of nitrosamine contamination
in sartan medicines has raised concerns regarding
the medication safety in many countries. Inevitably,
Taiwan was also affected that active pharmaceutical
ingredients (APIs) and ﬁnal products of 5 sartans
(candesartan cilexetil, irbesartan, losartan, olmesartan cilexetil and valsartan), and ﬁnal products of
2 sartans (azilsartan and telmisartan) were imported. It's required to develop an analytical method
for screening nitrosamines in pharmaceuticals. In
many studies, it focused on the detection of nitrosamines in water matrices [12,18,22,23]. For
example, Ripoll
es et al. developed a sensitive
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method for determination of 8 nitrosamines in water
which demonstrated a good performance of determination at a low concentration level [22]. Only few
works focused on screening nitrosamines in pharmaceutical matrices. Parr and Joseph have reviewed
the determination method of nitrosamines
including GC-based, LC-based and non-chromatographic methods [24]. Among those methods, LCMS/MS has various advantages in analysis
including less amount of sample usage, thermal
applicability of analytes and lower detection limit
for determination of nitrosamines in pharmaceuticals [25,26]. Therefore, this study aimed at establishing a feasible and sensitive method for screening
of 12 nitrosamines in sartans using LC-MS/MS,
whereas method validation was carried out. The
proposed method was further applied for the analysis of sartan APIs and ﬁnal products merchandised
in Taiwan.

2. Materials and methods
2.1. Chemicals and reagents
N-nitrosodiethylamine (NDEA), N-nitrosodimethylamine (NDMA), N-nitrosodipropylamine (NDPA), Nnitrosodimethylamine-d6 (NDMA-d6) and N-nitrosodipropylamine-d14 (NDPA-d14) were purchased
from
AccuStandard
(CT,
USA).
N-nitrosoethylisopropylamine (NEIPA) was purchased from
BOC Sciences (NY, USA). N-nitrosodiisopropylamine
(NDiPA) was purchased from Chem Service (PA,
USA). N-nitrosodiethanolamine (NDELA), N-nitrosomorpholine (NMOR) and N-nitrosopyrrolidine
(NPYR) were purchased from SigmaeAldrich (MO,
USA). N-nitrosopiperidine (NPIP) was purchased
from Supelco (PA, USA). N-nitrosodiisopropanolamine (NDiPLA), N-nitroso-N-methyl-4-aminobutyric
acid (NMBA), N-nitrosomethylethylamine (NMEA),
N-nitrosodiethylamine-d4
(NDEA-d4),
N-nitrosodiethanolamine-d8 (NDELA-d8), and N-nitroso-Nmethyl-4-aminobutyric acid-d3 (NMBA-d3) were purchased from TRC (ON, Canada). The chemical structures of 12 nitrosamines are shown in Fig. 1. 557
samples from 5 sartans, including candesartan cilexetil
(4 APIs and 6 ﬁnal products), irbesartan (35 APIs and
28 ﬁnal products), losartan (68 APIs and 198 ﬁnal
products), olmesartan cilexetil (8 APIs and 18 ﬁnal
products), and valsartan (65 APIs and 127 ﬁnal products), were collected and submitted by local public
health bureaus of Taiwan. The chemical structures of
5 sartans are shown in Fig. 2. Methanol and formic
acid of LC-MS grade were purchased from
SigmaeAldrich (MO, USA). Acetonitrile of LC-MS
grade was purchased from J.T Baker (NJ, USA). Water
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of LC-MS grade was purchased from Scharlau (Barcelona, Spain).
2.2. Instrumentation and chromatographic
conditions
The experiments were performed on a Waters
Acquity UPLC® (Waters Assoc., Milford, MA, USA)
coupled to a 6500 triple quadrupole linear ion
trap mass spectrometer (MS) equipped with an atmospheric-pressure chemical ionization (APCI)
source (AB Sciex, USA), and operated in multiple reaction monitoring (MRM) mode. The MRM parameters including MRM transitions, quantiﬁer, qualiﬁer,
collision energy and declustering potential are provided in Table 1. The chromatographic separation was
carried out on a trifunctional alkyl C18 bonded phase
column Xselect® HSS T3 column (15 cm  3 mm i.d.,
3.5 mm) (Waters Assoc., Milford, MA, USA) at 40  C
with a constant ﬂow rate of 0.6 mL/min using gradient
elution of mobile phase A consisting of 0.1% formic
acid in water and mobile phase B consisting of 0.1%
formic acid in acetonitrile/methanol (2:8). Each sample
was analyzed with an injection volume of 10 mL. The
total chromatographic run time was 15 min. The
elution was performed with varied gradient as follows:
0e1.0 min 5% B, 1.0e5.0 min 5e50% B, 5.0e6.5 min
50% B, 6.5e7.5 min 50e65% B, 7.5e8.5 min 65% B,
8.5e9.5 min 65e100% B, 9.5e12.0 min 100% B, and
12.1e15.0 min 5% B for equilibrium. After the injection of each sample, the needle was rinsed alternately
with methanol and water. A two-position diverter
valve was used and settings were as follows: detector
over 0e8.5 min, waste over 8.5e15.0 min. The MS ion
source was set as APCI in positive mode, under the
following conditions: temperature, 400  C; curtain gas
pressure, 25 psi; collision gas pressure of medium
level, ion source gas, 50 psi; and nebulizer current,
5 mA. The selectivity for precursor ion (Q1) and
product ions (Q3) was set to 0.7 m/z (FWHM).
2.3. Robustness
To examine the robustness of the proposed method,
the effect of deliberation variations was investigated
by following parameters such as mobile phase additive (0.1e0.2% formic acid), organic components of
mobile phase (20e40% acetonitrile in methanol) and
ﬂow rate of mobile phase (0.3e0.6 mL/min).
2.4. Preparation of standard solutions
Stock solutions of 12 nitrosamines and 5 internal
standards (IS) were prepared in methanol at
1000 mg/mL and 50 mg/mL, respectively. The internal

standard solution was prepared by diluting the internal standard stock solution with methanol to a
concentration of 400 ng/mL prior to use. A series of
working standard solutions for calibration curve
were prepared at concentrations of 2.5, 5.0, 10.0,
20.0, 25.0 and 50.0 ng/mL with 20 ng/mL of the internal standard. All the stock and working solutions
were stored at 30  C and acclimated to room
temperature prior to use.
2.5. Sample preparation
Transfer 250 mg of sartan API (or ground tablet
powder of ﬁnal product) to a 15 mL centrifuge tube.
Add 250 mL of the internal standard solution
(400 ng/mL) as well as 250 mL of methanol (for
validation, 250 ml of nitrosamine standard solution at
concentration of interest was added) to the tube, and
sonicated for 5 min to make an extraction solution.
Add 4.5 mL of DI water to the extraction solution
above and sonicate for 5 min. Centrifuge the sample
solution at 3000 g for 5 min, ﬁlter the solution
through a 0.22 mm PVDF ﬁlter, and then collect the
ﬁltrate, which was used as the sample solution.
2.6. Method validation
2.6.1. Linearity and sensitivity
The linearity was assessed by analyzing standard
solutions of 12 nitrosamines (n ¼ 3) at 6 concentrations ranging from 2.5 to 50.0 ng/mL by plotting the
peak area ratio of standard/internal standard versus
the concentration of standard using the leastsquares method estimated by logistic regression.
The linearity is acceptable when the correlation coefﬁcient r was higher than 0.995. The sensitivity of
the method was evaluated using the limit of detection (LOD) and limit of quantiﬁcation (LOQ) according to ICH validation of analytical procedures
[27]. The LOD is the lowest concentration of analyte
that can be detected with the estimated signal-tonoise (S/N) ratio of 3. The LOQ is the lowest concentration of analyte that can be quantiﬁed with the
suitable precision and accuracy using an estimated
S/N ratio of 10.
2.6.2. Accuracy and precision
Before assessing the accuracy (expressed as recovery, %), all sartan matrices were examined to be
absent of nitrosamines and so that the interference
to standards could be avoided. The accuracy was
evaluated by introducing quality control (QC) for
nitrosamines in sartan materices [27]. The procedure was in reference of ICH and followed the criteria
for QC in chemical analysis set up by TFDA (for
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Fig. 1. Chemical structures of 12 nitrosamines analyzed in this study.

Fig. 2. Chemical structures of 5 sartans analyzed in this study.
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Table 1. MRM parameters of 12 nitrosamines and 5 internal standards.
Analyte

RT (min)

MRM transitions

DP (V)

CE (eV)

29

17
9
15
21
17
20
17
28
8
16
16
27
22
37
13
29
21
33
14
22
13
22
14
21
8
25
9
16
46

(m/z)
NDELA

1.88

NDMA

2.7

NMOR

3.5

NDiPLA

3.75

NMBA

3.84

NMEA

3.95

NPYR

4.0

NDEA

5.3

NPIP

5.62

NEIPA

6.27

NDiPA

7.46

NDPA

8.15

NDELA-d8
NDMA-d6
NMBA-d3
NDEA-d4
NDPA-d14

1.87
2.65
3.82
5.25
7.99

135 > 74a
135 > 104b
75 > 58a
75 > 43b
117 > 87a
117 > 86b
163 > 88a
163 > 70b
147 > 117a
147 > 87b
89 > 61a
89 > 29b
101 > 55a
101 > 41b
103 > 75a
103 > 47b
115 > 69a
115 > 41b
117 > 75a
117 > 47b
131 > 89a
131 > 43b
131 > 89a
131 > 43b
143 > 111a
81 > 46a
150 > 120a
107 > 77a
145 > 50a

28
38
44
10
7
58
25
42
16
50
59
23
106
36
48
130

MRM, multiple reaction monitoring; RT: retention time.
a
Quantiﬁer.
b
Qualiﬁer; CE: collision energy; DP: declustering potential.

1.0e10.0 ng/mL, recovery 60e125%, RSD 30%; for
10.0e100.0 ng/mL, recovery 70e120%, RSD 20%).
The intra-day and inter-day accuracy (%) and precision (RSD in %) of the assay were assessed at 3
concentration levels from low to high within the
calibration curve (5.0, 25.0, and 50.0 ng/mL) in 3
replicates. The accuracy was assessed by comparing
the estimated concentration of analyte in matrix (A)
with that of standard solution (B), whereas the ratio
was calculated as following formula: A/B  100%.
The assessment was performed as follows: for intraday, 3 samples for each concentration, and 1 replicate for each sample, n ¼ 3; for inter-day, 3 samples
for each concentration, 1 replicate for each sample,
for 3 consecutive days, n ¼ 9.

3. Results and discussion
3.1. Optimization of chromatographic conditions
To optimize the chromatographic conditions, the
APCI was selected as the ionization source for
determination of nitrosamines in this study; nevertheless, ESI can also be applied as an alternative

when the target is not vaporized by APCI [27]. In the
literature, the advantages of APCI such better performance in selecting ions and less susceptible to
matrices for determination of nitrosamines have
been reported [22,28]. Preliminary tests were carried
out to assess the adaptability of ionization sources in
detecting nitrosamines. Accordingly, APCI showed
higher signals for all nitrosamines and thus selected
as the ionization source in this study. The MRM
chromatograms of 12 nitrosamines with APCI are
presented in Fig. 3. The MRM parameters with
APCI including are summarized in Table 1. Q1 and
Q3 for all analytes are within 0.7 m/z FWHM. Defects for some chromatograms were observed during analysis. A doublet peak of NDiPLA
chromatogram with same MRM transitions
appeared which may indicate the separation of
racemic mixture or zwitterions of NDiPLA analyzing
on Xselect® HSS T3 column. The peak shoulder
observed in the NMEA and NMBA chromatograms
was attributed to pH adaptation of mobile phase. All
the doublet peak and peak shoulder mentioned
above were adopted to reduce the deviation in
quantiﬁcation and validation.
3.2. Robustness
To evaluate the effect of mobile phase on separation, quantiﬁcation and peak width of analytes,
parameters such as additive (0.1e0.2% formic
acid), organic component (20e40% acetonitrile in
methanol) and ﬂow rate (0.3e0.6 mL/min) were
investigated. The results indicated that the conditions of mobile phase had only slight inﬂuence on
peak width (less than 0.1 min for all analytes)
which supports the robustness of the proposed
method.
3.3. Method validation
3.3.1. Linearity and sensitivity
The linearity of 12 nitrosamines was obtained up
to 50.0 ng/mL and the data are presented in Table 2.
The values of correlation coefﬁcient r were higher
than 0.995 for all analytes which indicated that the
most IS applied in qualiﬁcation were highly
recommendable for the targets analyzed in this
study. The LOD and LOQ determined for all analytes in sartan APIs and ﬁnal products were 20.0 ng/
g and 50.0 ng/g, respectively. In the literatures,
methods have been developed for determination of
nitrosamines in sartans. Schmidtsdorff and Schmidt
developed a method for determination of 9 nitrosamines (NDBA, NDEA, NDMA, NDPA, NDPhA,
NMEA, NMOR, NPIP and NPYR) using

supercritical ﬂuid chromatography which the LODs
ranged from 50 to 140 ng/g in valsartan and
20e460 ng/g in losartan [29]; el-Atma and Gutsche
reported a LC-MS/MS method for determination of
2 nitrosamines which the LODs for NDEA and
NDMA were 20 and 70 ng/g, respectively, while the
LOQs for NDEA and NDMA were 40 and 100 ng/g,
respectively [30]. Compared to the published
methods, this study demonstrated a variety of targets and sensitivity of detection for determination of
nitrosamines in sartans.

297

3.3.2. Accuracy and precision
The intra-day accuracy of nitrosamines for sartan
APIs was 81.4e117.0%, while the precision (RSD)
located in the range of 0.7e9.8%; for sartan ﬁnal
products, the value was 82.6e118.4%, while the
precision located in the range of 0.3e13.1%. The
inter-day accuracy of nitrosamines for sartan APIs
was 81.7e117.5%, while the precision located in the
range of 1.2e10.5%; for sartan ﬁnal products, the
value was 82.9e118.0%, while the precision located
in the range of 0.8e12.8%. The assessment of

Fig. 3. MRM chromatograms applying APCI ionization source for 12 nitrosamines and 5 internal standards.
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Fig. 3. (continued).
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Fig. 3. (continued).

accuracy and precision met the criteria (see section
2.6.2) for most nitrosamines within 5 sartan
matrices, except for NDiPA and NEIPA within
irbesartan matrix. The intra-day accuracy of NDiPA
for irbesartan API was 139.1e160.3%, where it was
97.3e124.1% for irbesartan ﬁnal products; the interday accuracy of NDiPA for irbesartan API was
140.3e176.9%, where it was 113.1e126.0% for irbesartan ﬁnal products. The intra-day accuracy of
NEIPA for irbesartan API was 64.5e70.3%, where it
was 47.5e49.3% for irbesartan ﬁnal products; the
inter-day accuracy of NEIPA for irbesartan API was
65.9e71.2%, where it was 46.3e48.9% for irbesartan
ﬁnal products. The result of accuracy and precision
for NDiPA (NEIPA) within irbesartan matrix indicated the chromatographic intensity was enhanced
(suppressed) owing to the matrix interference of
irbesartan, i.e. the intensity of corresponding internal standards NDPA-d14 (NDEA-d4) were enhanced
(suppressed) and resulted in the mis-estimation in
quantiﬁcation. To improve the disadvantage, the
corresponding internal standards for NDiPA and
NEIPA could be replaced by alternative isotropic
nitrosamines to receive a better performance in the
assessment of accuracy and precision.

Table 2. Linearity data of 12 nitrosamines.
Analyte

Linear
range (ng/mL)

Slope

Intercept

Correlation
coefficient (r)

NDELA
NDMA
NMOR
NDiPLA
NMBA
NMEA
NPYR
NDEA
NPIP
NEIPA
NDiPA
NDPA

2.5e50.0
2.5e50.0
2.5e50.0
2.5e50.0
2.5e50.0
2.5e50.0
2.5e50.0
2.5e50.0
2.5e50.0
2.5e50.0
2.5e50.0
2.5e50.0

0.23769
0.40608
0.34094
0.75543
0.82797
2.18029
2.23857
0.58442
2.06747
2.11105
27.90931
31.94901

0.00298
0.00448
0.00193
0.00435
0.00702
0.01566
0.02065
2.22599e-4
0.04224
0.00859
0.51163
0.85289

0.9989
0.9988
0.9993
0.9995
0.9977
0.9994
0.9992
0.9994
0.9983
0.9992
0.9994
0.9996

3.4. Analysis of authentic samples
557 samples from 5 different sartans acquired
from local public health bureaus were analyzed and
the result was shown in Fig. 4. A total of 98 positive
samples were detected from 557 authentic samples
which 3 sartan medicines, including irbesartan,
losartan, and valsartan were detected positive of
nitrosamines. Among those samples, valsartan had
the highest detection rate of nitrosamine-positive
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Fig. 4. Amount and detection rate of nitrosamine-positive samples from authentic samples.

Table 3. Amount and content of corresponding nitrosamine detected in positive samples.
Item

Valsartan
Losartan
Irbesartan
a

NDMA

NDEA

NMBA

NMOR

NPIP

Amounta
(pcs)

Content
(mg/g)

Amount
(pcs)

Content
(mg/g)

Amount
(pcs)

Content
(mg/g)

Amount
(pcs)

Content
(mg/g)

Amount
(pcs)

Content
(mg/g)

53
0
0

0.10e137.60
ND
ND

11
4
5

0.07e6.90
0.08e0.23
0.11e0.12

1
32
0

0.14
0.22e27.40
ND

2
0
0

0.16
ND
ND

2
0
0

0.12
ND
ND

Amount of contaminated samples sorted according to corresponding nitrosamine.

samples (29.17%), i.e. 56 out of 192 samples were
detected positive, followed by losartan (36/266,
13.53%) and irbesartan (6/63, 9.52%). The result of
detection was further interpreted to sort the types of
nitrosamines, and demonstrated in Table 3. 5 nitrosamines, including NDEA, NDMA, NMBA,
NMOR and NPIP, were detected in the 3 sartan
medicines mentioned above. For valsartan, most of
the positive samples (53/56) were detected having
NDMA, which the content attained to an enormous
level of 137.6 mg/g and indicated NDMA as the main
contaminant produced as by-product in the modiﬁcation of manufacturing process of valsartan. As to
losartan, the majority of the positive samples (32/36)
were detected having NMBA at the content level of
27.40 mg/g which posed that NMBA was the main
contaminant produced as by-product in the modiﬁcation of manufacturing process of losartan. For a
better understanding, all positive samples were
employed to examine if it is possible that more than
2 contaminants were detected in sartan medicines.
Not surprisingly, multiple nitrosamine contents
were found. In the positive samples of valsartan

medicines, 8 samples possessed 2 contaminants
NDMA and NDEA; 2 samples possessed 3 contaminants NDEA, NMOR and NPIP; 1 sample
possessed 3 contaminants NDEA, NDMA and
NMBA. Echo to the description in introduction, as
long the conditions were sufﬁcient, various nitrosamines would be produced which followed that the
modiﬁcation of sartan APIs manufacturing process
intensively affected the quality of pharmaceuticals
and led to the cross-border incident of medication
safety.

4. Conclusion
In this study, a multi-analyte LC-MS/MS method
was successfully developed for screening and
determination of 12 nitrosamines in sartan medicines. The proposed method was validated and
provided satisfactory result of validation for target
nitrosamines in most APIs and ﬁnal products which
demonstrated a good performance and speciﬁcity
for the method in screening and qualiﬁcation of
nitrosamines.
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